文献速递白血病

低甲基化药物改变急性髓系白血病免疫微环境并增强树突状细胞/AML疫苗免疫原性

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
PubMed 文献 · Br J Haematol · 2019-03-03

本文研究低甲基化药物guadecitabine对急性髓系白血病(AML)免疫微环境的调节作用及其与树突状细胞/AML融合疫苗联合应用的免疫增强效应。体外实验显示guadecitabine增强抗原加工与递呈,提高AML对T细胞杀伤的易感性;在免疫健全小鼠白血病模型中,guadecitabine减少PD-1阳性T细胞和髓源性抑制细胞扩增,增强白血病特异性免疫;联合疫苗可进一步增强抗白血病免疫和生存。作者认为该联合方案具有治疗潜力,计划开展临床试验。

要点

  • Guadecitabine增强AML抗原加工与递呈,提高其对T细胞杀伤的易感性。
  • Guadecitabine激活内源性逆转录病毒通路并放大炎症介质。
  • 在免疫健全小鼠中,guadecitabine减少PD-1阳性T细胞和髓源性抑制细胞扩增。

核心结论

  • Guadecitabine可改变AML免疫微环境并增强树突状细胞/AML融合疫苗的免疫原性,联合方案具有治疗潜力。

研究设计与样本

  • 本研究为体外实验与免疫健全小鼠白血病模型的临床前研究。

主要发现

  • Guadecitabine增强抗原加工与递呈,提高AML对T细胞介导杀伤的易感性。
  • Guadecitabine激活内源性逆转录病毒通路并下游放大关键炎症介质。
  • 在免疫健全小鼠白血病模型中,guadecitabine减少表达PD-1的T细胞并降低AML介导的髓源性抑制细胞扩增。
  • Guadecitabine治疗增强白血病特异性免疫,表现为靶向同系白血病细胞的CD4和CD8细胞增加。
  • Guadecitabine联合疫苗增强抗白血病免疫和生存。

临床怎么用

  • 作者认为新型个体化树突状细胞/AML融合疫苗与低甲基化药物联合具有治疗潜力,并计划开展临床试验研究该联合方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukaemia (AML) is a lethal haematological malignancy characterized by an immunosuppressive milieu in the tumour microenvironment (TME) that fosters disease growth and therapeutic resistance. Hypomethylating agents (HMAs) demonstrate clinical efficacy in AML patients and exert immunomodulatory activities. In the present study, we show that guadecitabine augments both antigen processing and presentation, resulting in increased AML susceptibility to T cell-mediated killing. Exposure to HMA results in the activation of the endogenous retroviral pathway with concomitant downstream amplification of critical mediators of inflammation. In an immunocompetent murine leukaemia model, guadecitabine negatively regulates inhibitory accessory cells in the TME by decreasing PD-1 (also termed PDCD1) expressing T cells and reducing AML-mediated expansion of myeloid-derived suppressor cells. Therapy with guadecitabine results in enhanced leukaemia-specific immunity, as manifested by increased CD4 and CD8 cells targeting syngeneic leukaemia cells. We have previously reported that vaccination with AML/dendritic cell fusions elicits the expansion of leukaemia-specific T cells and protects against disease relapse. In the present study, we demonstrate that vaccination in conjunction with HMA therapy results in enhanced anti-leukaemia immunity and survival. The combination of a novel personalized dendritic cell/AML fusion vaccine and an HMA has therapeutic potential, and a clinical trial investigating this combination is planned.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nahas MR, Stroopinsky D, Rosenblatt J, et al. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. Br J Haematol. 2019. PMID: 30828801. doi:10.1111/bjh.15818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。